PEN Form 4: Director Grewal Sells 186 Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
Harpreet Grewal, a director of Penumbra, Inc. (PEN), reported a sale of 186 shares of Penumbra common stock on 09/02/2025 at a reported price of $272.19 per share. After the transaction, the reporting person beneficially owned 8,888 shares, noting that a portion of those shares remains subject to vesting.
The filing states the sales were executed under the reporting person’s Rule 10b5-1 trading plan. The Form 4 was signed by an attorney-in-fact on behalf of Harpreet Grewal on 09/04/2025. No options, derivative transactions, or additional material details are disclosed in this filing.
Positive
- Sale executed under a Rule 10b5-1 trading plan, indicating the transaction was pre-authorized and intended to reduce concerns about insider timing
Negative
- Insider sale of 186 shares reduces the director's direct beneficial ownership to 8,888 shares; a portion of holdings is subject to vesting
Insights
TL;DR: A director sold a small number of shares under a pre-established 10b5-1 plan, reducing direct holdings to 8,888 shares.
The reported transaction is a routine director sale executed under a Rule 10b5-1 plan, which is commonly used to mitigate insider trading concerns by pre-specifying trades. The disclosure shows 186 shares sold at $272.19, leaving 8,888 beneficially owned shares with some subject to vesting. From a governance perspective, use of a 10b5-1 plan signals the trade followed a pre-authorized program rather than opportunistic timing. The filing contains no indication of derivative activity or other related-party transactions.
TL;DR: Director sale is documented and labeled as pursuant to a 10b5-1 plan; transaction size appears limited.
As reported, the director disposed of 186 shares at $272.19. The remaining beneficial ownership is stated as 8,888 shares, and the filing explicitly notes that some shares are subject to vesting. There are no reported acquisitions, option exercises, or other forms of compensation-related transfers in this Form 4. The concise disclosure is consistent with routine insider reporting obligations and does not provide additional context on timing or motivation beyond the 10b5-1 plan reference.
FAQ
What did Harpreet Grewal report on Form 4 for PEN?
Was the PEN insider sale part of a 10b5-1 plan?
Are there any derivative transactions reported by Harpreet Grewal?
Does the filing indicate any shares are unvested?
Who signed the Form 4 for Harpreet Grewal?